171 related articles for article (PubMed ID: 34034855)
1. Comparison of Insulins Glargine and Degludec in Diabetic Rhesus Macaques (
Puglisi SC; Mackiewicz AL; Ardeshir A; Garzel LM; Christe KL
Comp Med; 2021 Jun; 71(3):247-255. PubMed ID: 34034855
[TBL] [Abstract][Full Text] [Related]
2. Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
Brøsen JMB; Agesen RM; Alibegovic AC; Ullits Andersen H; Beck-Nielsen H; Gustenhoff P; Krarup Hansen T; Hedetoft CGR; Jensen TJ; Stolberg CR; Bogh Juhl C; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
Diabetes Technol Ther; 2022 Sep; 24(9):643-654. PubMed ID: 35467938
[No Abstract] [Full Text] [Related]
3. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
[TBL] [Abstract][Full Text] [Related]
5. How conclusive is the CONCLUDE trial?
Del Prato S
Diabetologia; 2020 Apr; 63(4):692-697. PubMed ID: 31950229
[TBL] [Abstract][Full Text] [Related]
6. Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
Yamabe M
J Diabetes Investig; 2019 Nov; 10(6):1597-1598. PubMed ID: 31608592
[TBL] [Abstract][Full Text] [Related]
7. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
Yamamoto C; Miyoshi H; Fujiwara Y; Kameda R; Ichiyama M; Nomoto H; Kameda H; Nakamura A; Atsumi T
Endocr J; 2016; 63(1):53-60. PubMed ID: 26522272
[TBL] [Abstract][Full Text] [Related]
8. [Effects of long-acting insulin degludec on type 2 diabetic hemodialysis patients with poor glycemic control].
Wada K; Wada Y; Tsuruoka S
Nihon Jinzo Gakkai Shi; 2015; 57(5):872-7. PubMed ID: 26387380
[TBL] [Abstract][Full Text] [Related]
9. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.
Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T
Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of Human and Veterinary Point-of-Care Glucometers for Use in Rhesus Macaques (Macaca mulatta), Sooty Mangabeys (Cercocebus atys), and Chimpanzees (Pan troglodytes).
Clemmons EA; Stovall MI; Owens DC; Scott JA; Jones-Wilkes AC; Kempf DJ; Ethun KF
J Am Assoc Lab Anim Sci; 2016; 55(3):346-53. PubMed ID: 27177571
[TBL] [Abstract][Full Text] [Related]
11. Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine.
Stailey M; Conway SE
Consult Pharm; 2017 Jan; 32(1):42-46. PubMed ID: 28077204
[TBL] [Abstract][Full Text] [Related]
12. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non-inferiority randomized trial.
Kuchay MS; Mathew A; Mishra M; Surendran P; Kaur P; Wasir JS; Gill HK; Jain R; Gagneja S; Kohli C; Kumari P; Singh MK; Mishra SK
Diabet Med; 2023 Jan; 40(1):e15002. PubMed ID: 36354383
[TBL] [Abstract][Full Text] [Related]
14. Bridging dose of U-100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice-daily glargine users.
Thirumalai A; Chao JH; Kaleru T; Dong X; Mandava P; Khakpour D; Hirsch IB
Diabetes Obes Metab; 2024 May; 26(5):1868-1876. PubMed ID: 38418413
[TBL] [Abstract][Full Text] [Related]
15. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring.
King AB
J Diabetes Sci Technol; 2010 Jan; 4(1):151-4. PubMed ID: 20167179
[TBL] [Abstract][Full Text] [Related]
16. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
[TBL] [Abstract][Full Text] [Related]
17. Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study.
Miura H; Sakaguchi K; Otowa-Suematsu N; Yamada T; So A; Komada H; Okada Y; Hirota Y; Tamori Y; Ogawa W
Diabetes Obes Metab; 2020 Dec; 22(12):2356-2363. PubMed ID: 32744395
[TBL] [Abstract][Full Text] [Related]
18. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
20. A pilot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine.
Kuroda A; Tsuruo M; Aki N; Kondo T; Oguro Y; Tamaki M; Aihara KI; Endo I; Matsumoto T; Abe M; Matsuhisa M
Diabetol Int; 2017 Mar; 8(1):112-115. PubMed ID: 30603314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
